More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$531408966
EPS
-1.37
P/E ratio
--
Price to sales
0.51
Dividend yield
--
Beta
1.627532
Previous close
$5.57
Today's open
$5.54
Day's range
$5.42 - $5.71
52 week range
$2.74 - $8.09
show more
CEO
Sam Raha
Employees
2700
Headquarters
Salt Lake City, UT
Exchange
Nasdaq Global Select
Shares outstanding
95922196
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
Myriad Genetics Expands SRL Partnership in Japan to Support Future Growth
SALT LAKE CITY, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces an expansion of its collaboration with SRL, one of the Japan's largest and leading clinical laboratory testing companies, to enable local testing for BRACAnalysis® Diagnostic System in Japan, subject to regulatory approval. The collaboration is expected to improve the testing experience for patients and health care providers, while creating a foundation for broader Myriad offerings and long-term growth in Japan.
GlobeNewsWire • Nov 17, 2026

Myriad Genetics, Inc. (MYGN) Presents at 2026 UBS Global Healthcare Conference Transcript
Myriad Genetics, Inc. ( MYGN ) 2026 UBS Global Healthcare Conference November 10, 2026 1:15 PM EST Company Participants Samraat Raha - President, CEO & Director Ben Wheeler - CFO & Principal Accounting Officer Conference Call Participants Douglas Schenkel - UBS Investment Bank, Research Division Adam Wieschhaus - UBS Investment Bank, Research Division Presentation Douglas Schenkel UBS Investment Bank, Research Division All right. Good afternoon.
Seeking Alpha • Nov 10, 2026

Myriad Genetics, Inc. (MYGN) Q3 2026 Earnings Call Transcript
Myriad Genetics, Inc. ( MYGN ) Q3 2026 Earnings Call November 4, 2026 4:30 PM EST Company Participants Matthew Scalo - Senior Vice President of Investor Relations Samraat Raha - President, CEO & Director Ben Wheeler - CFO & Principal Accounting Officer Conference Call Participants William Bonello - Craig-Hallum Capital Group LLC, Research Division Kyle Boucher - TD Cowen, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Myriad Genetics Third Quarter 2026 Financial Earnings Conference Call.
Seeking Alpha • Nov 5, 2026

Myriad Genetics Q3 Earnings Call Highlights
Myriad Genetics NASDAQ: MYGN reported third-quarter revenue of $202.7 million, down 1% from a year earlier, as growth in cancer and mental health testing was offset by a decline in its prenatal business. The company raised its full-year revenue outlook and said early efforts to address reimbursement denials helped improve revenue per test.
MarketBeat • Nov 4, 2026

Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives
Highl ights Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year. Higher Cancer Care Continuum (CCC) product mix and continued progress on payer engagement and revenue cycle management initiatives drove total average revenue per test increases of 7% sequentially and 1% year-over-year, partially offset by total test volume declines of 1% and 2%, respectively.
GlobeNewsWire • Nov 4, 2026

Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates
Myriad Genetics (MYGN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to break-even earnings per share a year ago.
Zacks Investment Research • Nov 5, 2026

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that Myriad management will participate in three upcoming healthcare conferences. The UBS Global Healthcare Conference with a fireside chat on Tuesday, Nov. 10, 2026, at 1:15 pm ET.
GlobeNewsWire • Nov 2, 2026

Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
SALT LAKE CITY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces new data from the ongoing MONSTAR-SCREEN-3 study demonstrating the potential of its whole-genome sequencing (WGS)-based Precise MRD™ platform to support ultra-sensitive molecular residual disease (MRD) detection in patients with resectable colorectal and pancreatic cancers. The findings, which will be presented as part of the European Society for Medical Oncology (ESMO) Congress 2026, reinforce the role of highly sensitive MRD testing after curative-intent surgery in tumor types where earlier insight into recurrence risk may help inform monitoring and treatment decisions.
GlobeNewsWire • Oct 22, 2026

Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
Labcorp Holdings Inc. (NYSE:LH) has agreed to acquire the prenatal health testing business of Myriad Genetics Inc. (NASDAQ:MYGN) in an all-cash transaction valued at $210 million, plus the value of the unit's inventory upon closing.
Benzinga • Oct 20, 2026

Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
SALT LAKE CITY and BURLINGTON, N.C., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, and Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announce they have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel®, Foresight®, SneakPeek®, and FirstGene® tests, to Labcorp for $210 million in cash, plus the value of the inventory of the Prenatal Health testing business at closing.
GlobeNewsWire • Oct 20, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Myriad Genetics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.